Cheneau Edouard, Wu Zhiyong, Leborgne Laurent, Ajani Andrew E, Weissman Neil, Pichard Augusto D, Satler Lowell F, Kent Kenneth M, Mintz Gary, Waksman Ron
Washington Hospital Center, Washington, DC 20010, USA.
Am Heart J. 2003 Jul;146(1):142-5. doi: 10.1016/S0002-8703(03)00147-9.
Vascular brachytherapy (VBT) reduces in-stent restenosis (ISR). However, additional stenting at the time of radiation may be associated with a worse outcome.
Intravascular ultrasound (IVUS) was performed after VBT and at 6 months follow-up in 79 native artery ISR patients treated with gamma-radiation who participated in the Washington Radiation for In-Stent restenosis Trial (WRIST), Gamma-1, and Angiorad Radiation Technology for In-Stent restenosis Trial in Coronaries (ARTISTIC) trials. Patients were treated with (192)Ir at 14 or 15 Gy at 2 mm from the source. Additional stents were used to treat the ISR lesions in 45 patients; these patients were then compared with the 34 patients treated without restenting. Paired measurements included stent, lumen, and intimal hyperplasia volumes. After the VBT procedure, intimal hyperplasia volume was smaller in the group treated with additional stents (54 +/- 33 mm(3) vs 34 +/- 33 mm(3), P =.012), but minimal lumen area was similar between the 2 groups (4.3 +/- 1.5 mm(2) vs 4.7 +/- 1.4 mm(2) respectively, P = NS). Between the time of the VBT procedure and follow-up, intimal hyperplasia volume increased by 27 +/- 19 mm(3) in the restented group and by 9 +/- 21 mm(3) in the group treated without additional stents (P =.014). At 6 months, intimal volume was similar in the 2 groups, but minimal lumen area was slightly smaller in the group treated with additional stents (3.4 +/- 1.8 mm(2) vs 4.2 +/- 1.7 mm(2), P =.053). Patients treated with additional stents had more target lesion revascularizations than the group treated without additional stents (38% vs 15%, P =.02).
Additional stenting reduces intimal hyperplasia within the stents acutely. However, it compromises the benefit of VBT by promoting higher intimal regrowth within months after radiation.
血管内近距离放射治疗(VBT)可减少支架内再狭窄(ISR)。然而,放疗时额外置入支架可能与更差的预后相关。
在参与华盛顿支架内再狭窄放射治疗试验(WRIST)、伽马-1试验以及冠状动脉支架内再狭窄的血管内放射技术试验(ARTISTIC)的79例接受伽马射线治疗的原位动脉ISR患者中,于VBT后及6个月随访时进行血管内超声(IVUS)检查。患者在距源2 mm处接受14或15 Gy的(192)Ir治疗。45例患者使用额外的支架治疗ISR病变;然后将这些患者与34例未再次置入支架治疗的患者进行比较。配对测量包括支架、管腔和内膜增生体积。VBT术后,使用额外支架治疗的组内膜增生体积较小(54±33 mm³对34±33 mm³,P = 0.012),但两组间最小管腔面积相似(分别为4.3±1.5 mm²对4.7±1.4 mm²,P =无显著差异)。在VBT术后至随访期间,再次置入支架组内膜增生体积增加27±19 mm³,未置入额外支架治疗的组增加9±21 mm³(P = 0.014)。6个月时,两组内膜体积相似,但使用额外支架治疗的组最小管腔面积略小(3.4±1.8 mm²对4.2±1.7 mm²,P = 0.053)。使用额外支架治疗的患者靶病变血运重建比未使用额外支架治疗的组更多(38%对15%,P = 0.02)。
额外置入支架可急性减少支架内的内膜增生。然而,它通过在放疗后数月内促进更高的内膜再生而损害了VBT的益处。